Vera releases final Phase 3 results showing kidney function stabilization
1 Sep 15 6:30 AM · 9d ago · 4 articles · 1 post · 3 sources · development 1 of 1
Vera Therapeutics announced final, two-year results from the Phase 3 ORIGIN 3 trial, demonstrating that Trutakna stabilized kidney function and reduced the risk of kidney-related death and other complications in IgAN patients. The company said it will seek full FDA approval during the fourth quarter based on these data.
“Trutakna stabilized kidney function and reduced the risk of kidney-related death and other complications in patients with a chronic autoimmune kidney disease”
Vera TherapeuticsVera Therapeutics Drug developerFDA Regulatory authority
The whole story articlesposts the bright band is this development · numbered dots are the others · click one to jump
What was reported 2 claims about this development
-
first by STAT News, 9d ago · also STAT
1 more headline
-
first by FirstWord Pharma, 8d ago
What people said 1 voice · verbatim
-
S
Vera Therapeutics said that its recently approved drug Trutakna stabilized kidney function and reduced the risk of kidney-related death and other complications in patients with a chronic autoimmune kidney disease. https://www. statnews.com/2026/09/15/vera-k idney-drug-trutakna-shows-strong-phase-3-results-igan/
All 1 developments of Vera's Trutakna shows strong Phase 3 results for IgA… →
NewswiresMastodonGoogle News